Ainos (formerly known as Amarillo Biosciences) is a healthcare company that specializes in the discovery and development of novel biopharmaceuticals, medical treatments, and specialty consumer products. It is engaged in the clinical trials of low-dose oral interferon as a therapeutic treatment for thrombocytopenia, Sjögren's syndrome, hepatitis C virus (HCV), and influenza indications. In addition, the company develops a treatment to address metabolism related diseases such as T1 and T2 diabetes using a pulsatile insulin infusion therapy that mimics the normal pancreas’ functions.